Introduction {#sec1}
============

Patients with low or intermediate risk prostate cancer have improved disease outcome in terms of local control, biochemical control, and disease-free survival if they are treated with dose-escalated rather than "standard-dose" conformal radiotherapy (CFRT) according to five randomized controlled trials from North America, The Netherlands, and the UK. However, dose-escalated radiotherapy has more late gastrointestinal effects and not bladder toxicity [@bib1; @bib2; @bib3; @bib4; @bib5; @bib6; @bib7]. Long-term survival after treatment is the rule [@bib9]; thus, patients who develop significant side effects from radical radiotherapy may have to live with them for a prolonged period of time.

The Medical Research Council (MRC) RT01 trial was a large, multicenter, randomized controlled trial in men with localized prostate cancer, who were randomized to receive either standard (64-Gy) or dose-escalated (74-Gy) CFRT. All patients received neoadjuvant hormone therapy. The design, patient, and treatment data and toxicity and early outcome results [@bib6; @bib7; @bib8] have been presented in detail: at 5 years, the cumulative incidence for RTOG grade ≥2 bowel toxicity was 24% for the standard-dose group and 33% for the escalated-dose group [@bib6; @bib7; @bib8]. We report here the detailed analysis of late bowel toxicity.

Methods and Materials {#sec2}
=====================

The MRC RT01 trial recruited men with T1b to T3a, N0, M0 prostate cancer, with a prostate-specific antigen concentration of ≤50 ng/ml. Patients received androgen suppression for 3 to 6 months before radiotherapy started. Patients were randomized to receive either 64 Gy in 32 fractions (standard group) or 74 Gy in 37 fractions (escalated group) [@bib6; @bib7]. The dose to rectum, small bowel, and anal canal was not routinely calculated during the planning process, and no attempt was made to reduce normal tissue doses. Patients were assessed for toxicities before starting androgen suppression, before starting radiotherapy, and at 6, 12, 18, and 24 months and annually thereafter. Only events reported at least 6 months after starting radiotherapy were deemed late events. Events occurring earlier were considered early toxicities, and descriptions have been published previously [@bib6].

Toxicity assessment {#sec2.1}
-------------------

Three physician-completed toxicity assessments were used: the Radiation Therapy Oncology Group (RTOG) [@bib10] scale, the Royal Marsden Hospital (RMH) scale [@bib5], and the Late Effects on Normal Tissue, Subjective, Objective, Management (LENT/SOM) questionnaire [@bib11]. The RTOG scale used matched that from the pilot study, measuring five bowel toxicities separately [@bib10]. It was not completed at preradiotherapy assessments. The RMH scale consists of five questions assessing the commonest bowel side effects after pelvic radiotherapy. The LENT/SOM instrument divides toxicity into subjective symptoms reported by patients (*e.g.,* pain), objective symptoms (*e.g.*, diarrhea), and medical intervention required to control toxicity (*e.g.,* medications or transfusions). Additionally, patients completed UCLA Prostate Cancer Index (UCLA-PCI) [@bib12] and Functional Assessment of Cancer Therapy-Prostate (FACT-P) [@bib13] scales to assess quality of life. These questionnaires asked 27 questions about bowel symptoms.

Responses to RTOG questions were categorized as grades 0, 1, 2, and ≥3 for this analysis. LENT/SOM grades 0 to 1 were broadly equivalent to RTOG grade 0; therefore, LENT/SOM grades 2, 3, and 4 translated to RTOG grades 1, 2, and ≥3. However, LENT/SOM diarrhea grade 1 was similar to RTOG grade 1 severity, and so it was categorized as 0, 1, 2, and ≥3 (see [Table E1](#appseca1){ref-type="sec"} in the supplementary material). The RMH, UCLA-PCI, and FACT-P questions did not have standard combined scales, so each variable from these questionnaires was considered individually, with response categories designated mild, moderate, or severe (see [Table E1](#appseca1){ref-type="sec"} in the supplementary material). The composite RTOG score has previously been reported [@bib7] and is not detailed additionally here.

Statistical analyses {#sec2.2}
--------------------

Analyses used a two-sided, 5% significance level on an intention-to-treat basis, with randomized patients analyzed according to their allocated treatment group. All analyses were performed using Stata (version 9) software.

Standard time-to-event (survival analysis) methodology was used to assess the first reported incidence of each severity level of each toxicity endpoint. Events were timed from the start of radiotherapy, and the differences between the treatment groups were tested using the log-rank test. Relative risks of these unwanted effects according to treatment are summarized using hazard ratios (HR) with 95% confidence intervals (CI) from Cox regression models. All comparisons are expressed relative to the standard group; so an HR value of \<1.00 indicates lower risk of toxicity in the escalated-dose group.

The prevalence of each grade of toxicity at each time point (including pretreatment) is presented in tables and as stacked bar graphs; no formal statistical tests have been performed with these data. These graphs present all data collected between 10% below and 30% above a certain time point in days, to a maximum of 6 months. Only patients for whom all five assessments were available for a certain time point were included in these analyses. Data for these analyses were frozen in March 2007; thus, this work is based on the same dataset as the efficacy results paper, which contained an overview of toxicity results [@bib7].

Results {#sec3}
=======

Between January 1998 and December 2001, 843 men were randomized to MRC RT01: 422 men were allocated to the escalated-dose arm, and 421 men were allocated to the standard arm. Compliance with the allocated treatment was excellent, with 95% of the standard and 97% of the escalated patients receiving the correct radiotherapy dose. At the preradiotherapy time point, all five forms were returned for 702/843 (83%) patients. Compliance with all scales at 6, 12, and 24 months was 605/764 (79%) patients, 645/790 (82%) patients, and 592/762 (78%) patients, respectively, and was 306/592 (52%) patients at 5 years.

Rectal bleeding {#sec3.1}
---------------

Clinicians recorded low baseline levels of rectal bleeding for 34/702 (5%) patients having mild and 4/702 (1%) patients having moderate bleeding on the RMH scale, and 10/702 (1%) patients having grade 2 on the LENT/SOM scale. Rectal bleeding was the most commonly reported bowel toxicity, with a cumulative incidence by 5 years for mild-or-worse bleeding on the RMH scale at 43% (170 patients) for the standard group and 53% (211) for the escalated group ([Table 1](#tbl1){ref-type="table"}). Escalated patients were significantly more likely to report mild-or-worse bleeding and moderate-or-worse bleeding, according to the RMH scale (mild-or-worse HR = 1.32; 95% CI, 1.08-1.61; moderate-or-worse HR = 1.97; 95% CI, 1.37-2.84). They were also significantly more likely to report grade ≥2 and grade ≥3 bleeding on the LENT/SOM objective scale (grade ≥2 HR = 1.55; 95% CI, 1.17-2.04; grade ≥3 HR = 3.12; 95% CI, 1.63-6.01). Severe bleeding was rare; by 5 years from starting radiotherapy, just 3 standard and 5 escalated patients reported the most severe RMH toxicity; 3 and 1 patients reported the most severe LENT/SOM toxicity. Escalated patients required more medical interventions for bleeding (LENT/SOM bleeding management), but the difference was not statistically significant: by 5 years, 17 escalated patients had required ≥1 transfusion or laser treatment, 8 escalated patients had required more regular transfusions, and 4 escalated patients required surgery compared with 9, 3, and 1 patients in the standard arm, respectively. After 6 months, the escalated arm patients had a higher prevalence of any bleeding toxicity at almost every time point ([Fig. 1](#fig1){ref-type="fig"}). Incidence peaked around 3 years after radiotherapy, and at 5 years, levels remained higher than those at baseline in both arms. The slowly rising overall incidence was due to new reports of bleeding up to 5 years postradiotherapy. For example, between 2 and 5 years after radiotherapy, 28 occurrences of LENT/SOM grade ≥2 objective bleeding were reported by patients in the standard arm who had not previously reported this symptom (compared to 83 reports in total over 5 years) and 35 occurrences were reported in the escalated arm (compared to 121 over 5 years). The prevalence of bleeding decreased from year 3 to year 5.

Diarrhea and frequency {#sec3.2}
----------------------

Incidence of diarrhea or loose stools was low preradiotherapy according to physician-reported scores, with 38/702 (5%) patients reporting mild symptoms and 4/702 (1%) patients reporting moderate symptoms on the RMH questionnaire. Patients reported higher levels of problems. Mild diarrhea was frequently reported in both treatment arms throughout the observation period, both before and after radiotherapy, with 341, 16, and 6 of 702 (49%, 2%, 1%, respectively) patients reporting mild, moderate, and severe loose stools, respectively on the UCLA-PCI preradiotherapy questionnaire; the corresponding numbers for abdominal cramps on the same questionnaire were 122 (18%), 38 (5%), and 17 (2%) of 702 patients, respectively.

Moderate-to-severe diarrhea was more commonly reported by physicians in the escalated arm, and this difference was statistically significant for several items in this category ([Table 2](#tbl2){ref-type="table"}), in particular, RTOG grade ≥2 (HR = 1.59; 95% CI, 1.07-2.35) and grade ≥3 (HR = 3.04; 95% CI, 1.21-7.67). However, grade ≥3 diarrhea was not common, with only 5 standard and 16 escalated arm patients reporting such severe symptoms by 5 years. Once more, escalated patients required more medical interventions according to LENT/SOM management of tenesmus/stool frequency, but the difference was not significant: the cumulative incidence by 5 years of receiving medication more than twice-weekly to control diarrhea was 6% (*n* = 23 patients) for standard and 8% (*n* = 32 patients) for escalated patients, while 4 and 9 patients, respectively, had needed multiple drugs daily. No patients reported surgical procedures for diarrhea. Physician-reported prevalence of diarrheal symptoms lessened once patients reached about 3 years from radiotherapy, although this was less clear for patient-reported outcomes. At most time points, prevalence was higher in the escalated arm than in the standard arm ([Fig. 2](#fig2){ref-type="fig"}).

Proctitis {#sec3.3}
---------

Physician-reported proctitis symptoms were rare at baseline, the most common being subjective pain (LENT/SOM); mild symptoms were recorded for 6/702 (1%) patients. Patients reported problems more frequently than doctors, with 76/702 (11%) patients reporting mild rectal urgency at preradiotherapy on UCLA-PCI, 34/702 (5%) patients reporting moderate rectal urgency, and 12/702 (2%) patients reporting severe rectal urgency. On the RTOG scale, mild-to-moderate proctitis was a frequent event during follow-up; significantly more escalated than standard arm patients reported grade ≥2 symptoms during follow-up (HR = 1.64; 95% CI, 1.02-1.52) ([Table 3](#tbl3){ref-type="table"}). According to the LENT/SOM subjective scale, cumulative incidence of grade ≥2 tenesmus by 5 years was 13% (51 patients) for the standard arm and 17% (68 patients) for the escalated arm (HR = 1.28; 95% CI, 0.90-1.83). The other LENT/SOM proctitis symptoms were also more frequently reported in the escalated arm at all severities; this difference was statistically significant for grade ≥3 mucosal loss (HR = 2.81; 95% CI, 1.18-6.68) and grade ≥2 sphincter control (HR = 2.42; 95% CI, 1.19-4.89). For pelvic pain (LENT/SOM management of pain), by 5 years, 3 standard and 11 escalated patients required at least regular administration of nonnarcotic analgesics; and 1 standard and 3 escalated patients required regular administration of narcotic analgesics. Medical intervention for mucous discharge and fecal incontinence was rare (LENT/SOM management of sphincter control); in total, by 5 years, 3 standard and 9 escalated patients used pads at least intermittently; 2 and 5 patients, respectively, needed regular pads. There was no significant difference between the treatment arms in terms of mild or moderate rectal urgency (UCLA-PCI) ([Fig. 3](#fig3){ref-type="fig"}); however, escalated patients were significantly more likely to report severe symptoms (HR = 1.64; 95% CI, 1.11-2.42).

Serious bowel injury {#sec3.4}
--------------------

Severe side effects associated with older radiotherapy protocols (bowel obstruction, stricture, ulceration) were rarely reported in MRC RT01. Cumulative incidence of rectal ulcers by 5 years was 1% (*n* = 5 patients) in the standard arm and 4% (*n* = 14 patients) in the escalated arm; for rectal stricture, the corresponding proportions were 3% (*n* = 11 patients) and 2% (*n* = 8 patients), respectively. Just 7 standard and 3 escalated patients had reported bowel obstruction by 5 years.

Patient-reported bowel distress {#sec3.5}
-------------------------------

Preradiotherapy, 109/702 (16%) patients reported mild, 33 (5%) patients reported moderate, and 2 (\<1%) patients reported severe distress associated with bowel movements, on the UCLA-PCI questionnaire. Generally, the prevalence of distressing bowel movements and problem bowel habits (UCLA-PCI) at any level increased until 2 or 3 years from starting radiotherapy and then lessened; however, levels were generally still higher than baseline at 5 years in both arms ([Fig. 4](#fig4){ref-type="fig"}). By 5 years, the cumulative incidence was 4% (15 patients) in the standard and 5% [@bib16] in the escalated arm for severe distressing bowel movements and 6% [@bib19] and 8% [@bib28] for severe problems with bowel habits ([Table 4](#tbl4){ref-type="table"}). There were no statistically significant differences between the arms for these variables, but for all grades, the HR favored the standard arm.

Discussion {#sec4}
==========

After patients received dose-escalated CFRT for prostate cancer, we found a higher incidence and prevalence of late bowel side effects in the dose-escalated arm after 5 years\' follow-up. Rectal bleeding, as measured using the RMH and LENT/SOM objective bleeding scales, peaked at 24 to 36 months after radiotherapy; it then decreased by 5 years on both scales but remained higher than at pretreatment. Regarding the assessment of loose stools and bowel frequency, the RTOG, RMH, and LENT/SOM physician-based scales showed peak late reactions occurring at 12 to 18 months, after which levels returned to near pretreatment levels for the standard arm, with a slight excess for the escalated arm. It is particularly noteworthy that the UCLA-PCI loose stool scale, showing the same general pattern, demonstrates the prevalence and importance of recording baseline bowel disturbance. RTOG proctitis showed a peak at 18 to 36 months and then fell back to pretreatment levels; a similar pattern is seen with UCLA-PCI rectal urgency, with 5-year scores being similar to those at pretreatment. Although many of the scales showed a return to near baseline levels by 5 years, the UCLA bowel distress and problem bowel habit items were still in excess of pretreatment values by 5 years, after peaking at 12 months. The FACT-P "trouble with moving bowels" scale seemed insensitive to treatment effects. More detailed analysis of the interrelationship and correlations between the different scoring schemes will be presented in a future publication.

Like other trials, severe late side effects were very rare (\<1%) overall but did occur. Severe rectal bleeding, tenesmus, and rectal ulceration were more common in the dose-escalated group. By 5 years, 4% of standard and 5% of escalated arm patients had reported severe distress at some time because of altered bowel habits.

In this trial, we trained clinicians at different centers to use the same outlining techniques, and we used standardized planning techniques and employed a quality assurance program to minimize differences between treatment centers [@bib6; @bib7]. However, at planning, we did not limit the dose to the rectum, anal canal, or small bowel in either treatment arm; anatomical differences might therefore also contribute to normal tissue toxicity [@bib14; @bib15; @bib16; @bib17; @bib18]. We used portal imaging of pelvic bones but not other image-guided techniques; changes in prostate position and rectal volume during treatment were also likely to influence dose to normal tissues and toxicity [@bib19; @bib20; @bib21]. We used three clinician scoring systems [@bib5; @bib10; @bib11] and two patient quality of life questionnaires [@bib12; @bib13]. Compliance from clinicians and patients was generally good. Here, we used data only where all assessments were completed for a certain time point, so the data quality is high. As demonstrated, the scoring systems give different details and slightly different toxicity levels. We had to adjust the LENT/SOM scale downward for most bowel questions (but not diarrhea) to allow comparison with original RTOG and RMH scales. For future trials, further efforts to standardize reporting of late side effects are required [@bib22; @bib23; @bib24; @bib25; @bib26].

Allowing for the differences in radiation dose, treatment techniques, toxicity scales, and follow-up time, our results are comparable with results of four published, randomized dose escalation trials ([Table 5](#tbl5){ref-type="table"}) [@bib1; @bib2; @bib4; @bib5]. Across these trials, the increase in RTOG grade ≥2 toxicity varied, perhaps reflecting differences in dose increments between the standard and escalated schedules (8 Gy and 10 Gy), planning techniques which included initial conventional planning [@bib1], full conformal therapy throughout [@bib2; @bib5] or proton beam boost [@bib4], toxicity scales, and reporting time points. Although each trial demonstrated improvements in biochemical control, patients with prostate cancer may rate quality of life and freedom from troublesome side effects as important as cancer control, and a significant proportion might choose lower radiation doses because of the worries of late side effects [@bib27; @bib28]. These results should encourage clinicians to discuss with patients the balance of expected benefits and risks of treatment. Future research might usefully assess the contribution of improved dose distributions and normal tissue sparing using intensity-modulated radiation therapy and image guidance to reduce treatment margins [@bib29], the application of appropriate dose constraints [@bib30], and perhaps focal radiation boosts [@bib31] with the aim of maintaining the benefits of disease control with dose escalation while reducing late side effects of treatment.

Conclusions {#sec5}
===========

Dose-escalated radiotherapy is associated with a statistically significant increased risk of rectal bleeding, which decreases over time. The cumulative incidence by 5 years for moderate-or-worse bleeding was higher in the escalated-dose arm. Diarrhea and proctitis were less common than bleeding. Worrying historical side effects (obstruction, ulceration, and fistulas) were very rare. Patient-reported bowel distress occurred uncommonly, and many toxicities reported seemed not to greatly trouble patients. Additional improvements in radiotherapy technique might maintain the benefits of dose escalation yet further improve patient acceptability.

Supplementary Data {#appseca1}
==================
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![Prevalence and cumulative incidence of rectal bleeding. (A, B) RMH; (C, D) LENT/SOM. Obj = objective; Std = standard arm, 64 Gy; Esc = escalated arm, 74 Gy; m = month; gr = grade; pre-H = prehormonal therapy; pre-RT = preradiation therapy.](gr1){#fig1}

###### 

Prevalence and cumulative incidence of diarrhea. (A, B) RTOG; (C, D) RMH; (E, F) LENT/SOM; (G, H) UCLA-PCI; (I, J) abdominal pain, UCLA-PCI. Subj = subjective; Std = standard arm; Esc = escalated arm; m = month; gr = grade; pre-H = prehormonal therapy; pre-RT = preradiation therapy.
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![Prevalence and cumulative incidence of proctitis. (A, B) RTOG; (C, D) rectal urgency, UCLA-PCI. Std = standard arm; Esc = escalated arm; m = month; gr = grade; pre-H = prehormonal therapy; pre-RT = preradiation therapy.](gr3){#fig3}

![Prevalence and cumulative incidence of patient distress and difficulties. (A, B) Bowel distress, UCLA-PCI; (C, D) problems with bowel habits, UCLA-PCI; (E, F) trouble moving bowels, FACT-P. Std = standard arm; Esc = escalated arm; m = month; gr = grade; pre-H = prehormonal therapy; pre-RT = preradiation therapy.](gr4){#fig4}

###### 

Cumulative incidence and risk of rectal bleeding

                                                       Cumulative incidence at 5 years              
  ------------------------------- ------ ------------- --------------------------------- ---- ----- ----
  Rectal bleeding: RMH                                                                              
   Mild                           1.32   1.08--1.61    170                               43   111   53
   Moderate                       1.97   1.37--2.84    43                                11   81    21
   Severe                         1.65   0.39--6.92    3                                 1    5     1
  Objective bleeding: LENT/SOM                                                                      
   Grade ≥2                       1.55   1.17--2.04    83                                22   121   32
   Grade ≥3                       3.12   1.63--6.01    12                                3    36    10
   Grade ≥4                       0.68   0.11--4.04    3                                 1    1     1
  Management bleeding: LENT/SOM                                                                     
   Grade ≥2                       1.54   0.74--3.20    9                                 3    17    4
   Grade ≥3                       3.07   0.83--11.33   3                                 1    8     2
   Grade ≥4                       5.12   0.60--43.8    1                                 0    4     1

###### 

Cumulative incidence and risk of diarrhea and frequency

                                                            Cumulative incidence at 5 years              
  -------------------------------------- ------ ----------- --------------------------------- ---- ----- ----
  Diarrhea: RTOG                                                                                         
  Grade ≥1                               1.06   0.84-1.34   130                               33   137   34
  Grade ≥2                               1.59   1.07-2.35   38                                10   60    15
  Grade ≥3                               3.04   1.21-7.67   5                                 1    16    4
  Bowel frequency: RMH                                                                                   
  Mild                                   1.12   0.89-1.41   139                               32   144   36
  Moderate                               1.38   0.92-2.07   35                                9    54    14
  Severe                                 2.23   1.09-4.55   9                                 2    24    6
  Subjective stool frequency: LENT/SOM                                                                   
  Grade ≥1                               1.07   0.87-1.32   172                               44   181   46
  Grade ≥2                               1.79   1.10-2.94   23                                6    43    12
  Grade ≥3                               NA     NA          0                                 0    9     2
  Management tenesmus: LENT/SOM                                                                          
  Grade ≥2                               1.42   0.83-2.42   6                                 23   8     32
  Grade ≥3                               2.28   0.70-7.41   1                                 4    2     9
  Grade ≥4                               NA     NA          0                                 0    0     0
  Loose stools: UCLA-PCI                                                                                 
  Mild                                   1.14   0.98-1.31   360                               91   378   94
  Moderate                               1.25   0.90-1.73   66                                17   77    21
  Severe                                 0.95   0.51-1.75   21                                6    20    6
  Pain abdomen: UCLA-PCI                                                                                 
  Mild                                   1.19   0.98-1.44   193                               51   223   58
  Moderate                               1.53   1.13-2.06   71                                21   103   28
  Severe                                 1.55   0.84-2.86   17                                5    26    7

*Abbreviation:* NA = not applicable.

###### 

Cumulative incidence and risk of proctitis

                                                                Cumulative incidence at 5 years              
  ---------------------------------------- ------ ------------- --------------------------------- ---- ----- ----
  Proctitis: RTOG                                                                                            
   Grade ≥1                                1.24   1.02--1.52    167                               42   199   50
   Grade ≥2                                1.64   1.20--2.25    58                                15   96    25
   Grade ≥3                                1.74   0.97--3.10    17                                4    29    7
  Subjective tenesmus: LENT/SOM                                                                              
   Grade ≥2                                1.28   0.90--1.83    51                                13   68    17
   Grade ≥3                                1.75   0.90--3.38    14                                4    23    6
   Grade ≥4                                NA     NA            0                                 0    1     0
  Subjective mucosal loss: LENT/SOM                                                                          
   Grade ≥2                                1.31   0.78--2.21    24                                6    31    8
   Grade ≥3                                2.81   1.18--6.68    6                                 2    18    5
   Grade ≥4                                NA     NA            0                                 0    1     0
  Subjective sphincter control: LENT/SOM                                                                     
   Grade ≥2                                2.42   1.19--4.89    10                                5    25    7
   Grade ≥3                                9.25   1.17--73.02   1                                 0    9     2
   Grade ≥4                                NA     NA            0                                 0    1     0
  Subjective rectal pain: LENT/SOM                                                                           
   Grade ≥2                                1.46   0.84--2.52    21                                5    31    8
   Grade ≥3                                7.14   0.88--58.01   1                                 0    7     2
   Grade ≥4                                NA     NA            0                                 0    0     0
  Management sphincter control: LENT/SOM                                                                     
   Grade ≥2                                3.04   0.82--11.22   3                                 1    9     2
   Grade ≥3                                2.54   0.49--13.07   2                                 0    5     1
   Grade ≥4                                NA     NA            0                                 0    0     0
  Management pelvic pain: LENT/SOM                                                                           
   Grade ≥2                                3.76   1.05--13.47   3                                 1    11    3
   Grade ≥3                                3.07   0.32--29.53   1                                 0    3     1
   Grade ≥4                                NA     NA            0                                 0    1     0
  Rectal urgency: UCLA-PCI                                                                                   
   Mild                                    1.06   0.88--1.27    119                               57   231   61
   Moderate                                1.11   0.86--1.42    114                               32   125   34
   Severe                                  1.64   1.11--2.42    41                                11   66    19

###### 

Cumulative incidence of difficulties with bowel habits from patient questionnaires

                                                     Cumulative incidence at 5 years              
  ------------------------------ ------ ------------ --------------------------------- ---- ----- ----
  Bowel distress: UCLA-PCI                                                                        
   Mild                          1.08   0.91--1.29   258                               68   268   61
   Moderate                      1.26   0.96--1.64   101                               29   119   32
   Severe                        1.07   0.53--2.17   15                                4    16    5
  Bowel problems: UCLA-PCI                                                                        
   Mild                          1.09   0.89--1.35   167                               46   175   46
   Moderate                      1.21   0.92--1.59   96                                26   110   29
   Severe                        1.49   0.83--2.67   19                                6    28    8
  Trouble moving bowel: FACT-P                                                                    
   Mild                          1.01   0.83--1.22   211                               57   210   56
   Moderate                      1.39   0.94--2.05   42                                12   59    17
   Severe                        1.63   0.91--2.94   17                                5    29    9

###### 

Cumulative incidence of late RTOG grade ≥2 toxicity in five randomized trials

                                 Trial (ref.\[s\])                                                                                                                      
  ------------------------------ ----------------------------------------------------- -------------------------- -------------------------- -------------------------- ----------------------------
  RT dose Gy                     70 vs. 78                                             68 vs. 78                  70.2 vs 79.2               64 vs. 74                  64 vs. 74
  Setting                        US                                                    The Netherlands            US                         UK                         UK, Australia, New Zealand
  Sites                          Single site                                           Multisite                  Single site                Single site                Multisite
  RT technique                   CFRT photon                                           CFRT photon                CFRT photon                CFRT photon                CFRT photon
                                 CFRT boost                                            CFRT boost                 Proton boost               CFRT boost                 CFRT boost
  No. of patients randomized     301                                                   669                        393                        126                        843
  Toxicity scale                 RTOG-LENT modified[∗](#tblfn7){ref-type="table-fn"}   RTOG/EORTC                 RTOG                       RTOG original              RTOG original
  Median follow-up (years)       8.7                                                   5.8                        5.5                        6.2                        5.3
  Grade ≥2 64 Gy vs. 74 Gy       13% vs. 26% (*p* = 0.013)                             25% vs. 35% (*p* = 0.04)   9% vs. 18% (*p* = 0.005)   11% vs. 23% (*p* = 0.02)   24% vs. 33% (*p* = 0.005)
  Analysis time point and type   By 10 years cumulative                                By 7 years cumulative      "Late" snapshot            By 2 years cumulative      By 5 years cumulative

Composite score including rectal bleeding.
